d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The optimal duration of oral anticoagulation in patients with idiopathic venous thromboembolism is uncertain. Testing of D-dimer levels may play a role in the assessment of the need for prolonged anticoagulation. METHODS: We performed D-dimer testing 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months. Patients with a normal D-dimer level did not resume anticoagulation, whereas those with an abnormal D-dimer level were randomly assigned either to resume or to discontinue treatment. The study outcome was the composite of recurrent venous thromboembolism and major bleeding during an average follow-up of 1.4 years. RESULTS: The D-dimer assay was abnormal in 223 of 608 patients (36.7%). A total of 18 events occurred among the 120 patients who stopped anticoagulation (15.0%), as compared with 3 events among the 103 patients who resumed anticoagulation (2.9%), for an adjusted hazard ratio of 4.26 (95% confidence interval [CI], 1.23 to 14.6; P=0.02). Thromboembolism recurred in 24 of 385 patients with a normal D-dimer level (6.2%). Among patients who stopped anticoagulation, the adjusted hazard ratio for recurrent thromboembolism among those with an abnormal D-dimer level, as compared with those with a normal D-dimer level, was 2.27 (95% CI, 1.15 to 4.46; P=0.02). CONCLUSIONS: Patients with an abnormal D-dimer level 1 month after the discontinuation of anticoagulation have a significant incidence of recurrent venous thromboembolism, which is reduced by the resumption of anticoagulation. The optimal course of anticoagulation in patients with a normal D-dimer level has not been clearly established. (ClinicalTrials.gov number, NCT00264277 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
Heit, J. A., Mohr, D. N., Silverstein, M. D., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.761 · Cited by 1,352
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Self-citationO'Neill, D. D., Westerman, D. P., & Sacco, W. (1966) · doi:10.21236/ad0635168 · Cited by 566
Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I., Nony, P., Sanson, C., & Boissel, J.-P. (2001) · Circulation · doi:10.1161/01.cir.103.20.2453 · Cited by 408
Research works printed but not linked: 1
- Kearon C, 2003, CMAJ, 168, 183
Cited by
Items 401–500 of 619
Anar, M. A., Ansari, A., Erabi, G., Rahmanian, M., Movahedi, M., Chichagi, F., Deravi, N., Taghavi, F., Kazemi, B., Javanshir, E., et al. (2023) · PubMed Central · Cited by 5
Duration of anticoagulation treatment in patients with venous thromboembolism.
Kaatz, S., Qureshi, W., Fain, C., & Paje, D. G. (2010) · PubMed · Cited by 3
A practical approach to thrombophilia testing
Thachil, J. V. (2013) · British Journal of Hospital Medicine · doi:10.12968/hmed.2013.74.sup5.c94 · Cited by 3
D-Dimer Specificity for the Diagnosis of Acute Symptomatic Pulmonary Embolism
del Olmo, V. G. (2014) · Journal of Hematology & Thromboembolic Diseases · doi:10.4172/2329-8790.1000177 · Cited by 3
“In addition, the detection of lower D-dimer levels supports the possibility of suspending anticoagulant treatment in patients that have suffered a thromboembolic event, with continued high values suggesting the need to maintain the anticoagulant treatment indefinitely [7].”
BackgroundHenke, P. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00011-1 · Cited by 5
Back To Basics: Theory of Thrombus Formation and Potential Implications for Therapies?
Mosquera, M. S., & Diaz, J. A. (2023) · Techniques in vascular and interventional radiology · doi:10.1016/j.tvir.2023.100894 · Cited by 3
Weitz, J. I. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00098-1 · Cited by 3
Prognosis and Monitoring of VTE
Naddour, M., Kalani, M., Hattab, Y., Gandhi, V., Singh, A. C., & Bajwa, O. A. (2017) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000167 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
Tratamiento de la trombosis venosa profunda iliofemoral y del síndrome postrombótico
Botella, F. G., Gómez, M. L., Portolés, O., & Gadea, L. I. (2013) · Angiología · doi:10.1016/j.angio.2013.05.005 · Cited by 3
Kreidy, R. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613497423 · Cited by 3
“Ongoing hypercoagulopathy is an essential predictor of recurrent VTE risk.(19) Factor V Leiden, prothrombin G 20210 A, and MTHFR mutations leading to hyperhomocysteinemia are the most commonly observed prothrombotic genetic abnormalities associated with venous recurrence.”
BackgroundManaging pulmonary embolism using prognostic models: future concepts for primary care
Geersing, G., Oudega, R., Hoes, A. W., & Moons, K. G. M. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110213 · Cited by 3
“However, the impact of D-dimer testing on patient care has been evaluated in only one relatively small randomized controlled trial.(31) More studies, either observational or, preferably, larger randomized controlled trials, are needed.”
BackgroundEvaluation and Management of Chronic Pulmonary Thromboembolic Disease
Mendoza, V., & Scharf, M. (2011) · Hospital Practice · doi:10.3810/hp.2011.08.580 · Cited by 3
“patients with idiopathic DVT or PE who may benefi t from anticoagulation for 3 months.(24) They measured serum”
BackgroundHyers, T. M., Shetty, H. G. M., & Campbell, I. A. (2010) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2010.310 · Cited by 3
Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?
Carman, T. L. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.002 · Cited by 3
Antnez, M. G., Mguez, A. M., Carvajal, C. C., & Gonzlez-Cobos, C. L. (2007) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(07)74735-5 · Cited by 3
Venous Disease and Pulmonary Embolism
Moneta, G. L., & Foley, M. I. (2008) · Springer eBooks · doi:10.1007/978-0-387-68113-9_68 · Cited by 3
Couturaud, F., & Kearon, C. (2008) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2008.09.007 · Cited by 4
Venous thromboembolism: risk of recurrence and long-term anticoagulation
Khalil, L. Y., Wong, H., Keeling, D. M., & Desborough, M. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.2.72 · Cited by 3
The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy
Elmi, G., Pizzini, A. M., & Silingardi, M. (2018) · Vascular · doi:10.1177/1708538118776896 · Cited by 3
Thrombophilia: Assays and Interpretation
Yohe, S. L., & Olson, J. D. (2012) · Wiley eBooks · doi:10.1002/9781444398595.ch38 · Cited by 3
Dosage des D-dimères et risque de récidive thromboembolique veineuse
Righini, M., & Perrier, A. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.12.012 · Cited by 3
How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized?
Rana, P., & Levine, M. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6977 · Cited by 3
Akl, E. A., & Kearon, C. (2014) · doi:10.2217/fmeb2013.13.118 · Cited by 3
Roux, P. L., Robin, P., Pennec, R. L., Tromeur, C., Couturaud, F., Asselineau, J., Gal, G. L., & Salaün, P. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.102867 · Cited by 2
“Several clinical, biochemical, or imaging predictors of VTE recurrence have been identi fi ed, including age, male gender [8,9], obesity [10], some biologic thrombophilia [11,12], plasma D-dimer levels [13,14], or residual vein obstruction after deep vein thrombosis (DVT) [15].”
Weng, S., Ding, C., Hu, D., Huang, L., & Peng, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-14960-7 · Cited by 3
Huang, L., Gong, L., Chen, J., Chen, X., Yao, B., Wang, Z., & Weng, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1630099 · Cited by 2
Riesgo de recurrencia en la enfermedad tromboembólica venosa tras suspender la anticoagulación
Romero, J. M. C. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.06.023 · Cited by 2
Jiménez, D., & Uresandi, F. (2014) · Angiología · doi:10.1016/j.angio.2014.02.003 · Cited by 3
Kroeger, K., Pleye, J., Pourhassan, S., Peter, J., & Noppeney, T. (2018) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0612-8244 · Cited by 2
“[18] Palareti G, Cosmi B, Legnani C et al.”
BackgroundKomarov, A. L. (2019) · Kardiologiia · doi:10.18087/cardio.2019.2.10232 · Cited by 2
“Известно, что высокий уровень D-димера через 1 мес после прекращения приема антикоагулянтов является высоко значимым предиктором рецидивов ВТЭО [32, 33].”
Ferrari, É., Fourrier, E., Asarisi, F., Heme, N., Redjimi, N., Berkane, N., Labbaoui, M., Breittmayer, J. P., Bun, S. S., Moceri, P., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050910 · Cited by 4
Association of Haemostasis Activation Markers with Thrombophilia and Venous Thromboembolism
Cuderman, T. V., Mijovski, M. B., Antovič, A., Peternel, P., Kozak, M., & Stegnar, M. (2011) · InTech eBooks · doi:10.5772/26357 · Cited by 2
The role of soluble fibrin during anticoagulant therapy: a case report
Kawakami, T., Tanaka, N., Ishihara, H., & Ohno, H. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0053-1 · Cited by 2
“thrombin-fibrinogen reactions and is a potentially useful marker of hypercoagulability, while D-dimer is a small protein fragment and is detected only after a blood clot is degraded by fibrinolysis [7–12].”
BackgroundVenous thromboembolism: Diagnosis, treatment and the prevention of long-term complications
Barnes, G. D., Froehlich, J. B., Kanthi, Y. M., & Wakefield, T. W. (2014) · Reviews in vascular medicine · doi:10.1016/j.rvm.2014.07.005 · Cited by 2
Acute Deep Vein Thrombosis Cases in the Real World
Klein, S. J., & Vedantham, S. (2012) · Seminars in Interventional Radiology · doi:10.1055/s-0032-1302448 · Cited by 2
The Controversy of Managing Calf Vein Thrombosis: A Systematic Review
Masuda, E. M., Liquido, F., & He, Q. (2010) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2009.11.007 · Cited by 2
Disorders of pulmonary circulation
Pineo, G. F., & Hull, R. D. (2008) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32830a9393 · Cited by 2
Medical Management of Venous Thromboembolism: What the Interventional Radiologist Needs to Know
Kasthuri, R. S., & Key, N. S. (2012) · Seminars in Interventional Radiology · doi:10.1055/s-0032-1302445 · Cited by 2
Torbicki, A., Perrier, A., Konstantinides, S., & Bengel, F. M. (2016) · Cited by 2
Riesgo de recurrencia en el tromboembolismo venoso idiopático
Franco‐Moreno, A., Aracil, C. D. A., & Navarro, M. J. G. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.04.015 · Cited by 2
Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism
Joseph, L., & Bartholomew, J. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416652236 · Cited by 2
Shoji, T., Mizugaki, H., Ikezawa, Y., Furuta, M., Takashima, Y., Kikuchi, H., Goudarzi, H., Asahina, H., Kikuchi, J., Kikuchi, E., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9741-17 · Cited by 2
“Thus, treatment failure was suspected (9).”
Clinical Application of D-Dimer in Venous Thromboembolism
Kim, H., & Yun, S. S. (2020) · Annals of Phlebology · doi:10.37923/phle.2020.18.1.4 · Cited by 2
Murkamilov, I. T., Айтбаев, К. А., Fomin, V. V., Абдилалимовна, М. Ж., Yusupov, F. A., Aйдаров, З. А., & Bayzhigitova, A. A. (2021) · Bulletin of Science and Practice · doi:10.33619/2414-2948/62/15 · Cited by 2
‘Penelope test’: a practical instrument for checking appropriateness of laboratory tests
Caruso, S., Szőke, D., & Panteghini, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0368 · Cited by 2
Hemostasis from Bench to Bedside: The History of Three Successful Stories of Translational Medicine
Tripodi, A. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1758060 · Cited by 2
Self-citationBernát, S. I., & Rókusz, L. (2012) · Orvosi Hetilap · doi:10.1556/oh.2012.29350 · Cited by 2
Caractéristiques immuno-analytiques des D-dimères
Nougier, C., & Marijon, A. (2012) · Immuno-analyse & Biologie Spécialisée · doi:10.1016/j.immbio.2012.01.006 · Cited by 2
Casuccio, A., Bajardi, G., Bellisi, M. G., Attanzio, M. T., Cormaci, O., Pellegrino, M., Dolce, A., Siragusa, S., Malato, A., Anastasio, R., et al. (2008) · Cited by 2
D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs
Park, J. K., Koo, D. H., Yoon, D. H., & Lee, J. N. (2016) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2015.11.038 · Cited by 2
Superficial venous thrombosis: Single-center experience and current recommendations
Premkumar, P., Kalipatnapu, S., Selvaraj, D., & Agarwal, S. K. (2019) · Indian Journal of Vascular and Endovascular Surgery · doi:10.4103/ijves.ijves_25_19 · Cited by 2
Comerota, A. J. (2018) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2018.03.011 · Cited by 2
Betancourt, M. T., & Rodger, M. A. (2007) · Acta chirurgica Belgica · doi:10.1080/00015458.2007.11680138 · Cited by 2
“D-Dimer measured after OAT discontinuation in VTE patients has shown a high negative predictive value (NPV) for recurrent VTE, and elevated D-Dimer has been suggested as the most promising independent predictor of recurrence in unprovoked VTE patients (15-17).”
BackgroundEnfermedad tromboembólica venosa idiopática versus secundaria
Fuentes, D. S., & Beltrán, E. R. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.05.018 · Cited by 2
Update in General Internal Medicine
Harrington, D. W., & Munekata, M. T. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-2-200707170-00009 · Cited by 2
Preventing recurrent venous thromboembolism
(2009) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2009.03.0010 · Cited by 2
Caruso, S., Szőke, D., Birindelli, S., Falvella, F. S., Dolci, A., & Panteghini, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0389 · Cited by 2
Çelik, E., Araz, Ö., Kerget, B., Tezcan, A., Uçar, E. Y., Akgün, M., & Sağlam, L. (2022) · Heart & Lung · doi:10.1016/j.hrtlng.2022.06.025 · Cited by 1
Hudák, A., Pettkó‐Szandtner, A., Letoha, A., & Letoha, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168007 · Cited by 1
“%) than in COV − vac − group (1 of 9 patients; 11.1%), which could blunt infection-induced coagulopathy [20,21].”
InfluentialXu, Y., Khan, F. A., Kovacs, M. J., Sabri, E., Carrier, M., Righini, M., Kahn, S. R., Wells, P. S., Anderson, D. R., Chagnon, I., et al. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.012 · Cited by 1
The incidence of early recurrent venous thromboembolism: a systematic review and meta-analysis
Eischer, L., Kyrle, P. A., Kaider, A., Schmidt, A., Wildner, B., Boc, A., Bradbury, C. A., Undas, A., Couturaud, F., Minno, M. N. D. D., et al. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103317 · Cited by 1
Self-citationSalinas-Mendoza, S., Burgos-Cárdenas, Á. J., & Meléndez-Rhenals, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340158 · Cited by 1
Coagulation, genotypes and recurrent cardiovascular events: what further studies are required?
Lowe, G. D. O. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02947.x · Cited by 1
Predicting the future: it’s not a SNP
Keeling, D. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02922.x · Cited by 1
Clinical Year in Review of Venous Thromboembolism
Kim, Y. (2011) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2011.71.4.245 · Cited by 1
Recurrent pulmonary embolism in a boy with antiphospholipid syndrome
Müller, C., Willaschek, C., Borst, M. M., & Buchhorn, R. (2013) · Case Reports in Clinical Medicine · doi:10.4236/crcm.2013.25083 · Cited by 1
Clasificación y tratamiento de la embolia pulmonar aguda
Gabriel, F., Labiós, M., Ferreres, J., & Ibáñez, L. (2013) · Angiología · doi:10.1016/j.angio.2012.12.002 · Cited by 1
Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism
Conway, S. E., & Marcy, T. R. (2010) · Journal of Pharmacy Practice · doi:10.1177/0897190010366930 · Cited by 1
Identificación de factores de riesgo clínicos en la trombosis venosa profunda idiopática recurrente
Solá, M. L. D. R., Fajardo, J. A. G., & Puerta, C. V. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2015.10.031 · Cited by 1
d-Dimer Testing to Determine the Duration of Anticoagulation Therapy
Moneta, G. L. (2008) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(08)70905-9 · Cited by 1
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Tromeur, C., & Couturaud, F. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.005 · Cited by 1
“AVK ; [49] toutefois, chez les patients ayant un taux de Ddimères normal (sans reprise de traitement par AVK) le taux de récidive était intermédiaire (soit 4,6 %/an).”
BackgroundThe Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism
Prandoni, P. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_108 · Cited by 1
Anticoagulación extendida en la enfermedad tromboembólica venosa. A favor
Capitán, M. C. F. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.02.017 · Cited by 1
Identifying clinical risk factors in recurrent idiopathic deep venous thrombosis
Solá, M. L. D. R., Fajardo, J. A. G., & Puerta, C. V. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.05.002 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0738-6.00007-3 · Cited by 2
Plessier, A., & Shukla, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-08552-9_53 · Cited by 1
Duration of anticoagulation of venous thromboembolism
Couturaud, F., Meneveau, N. F., Sevestre, M., Morange, P., & Jiménez, D. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104245 · Cited by 1
del Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.10.004 · Cited by 1
Anticoagulation for Venous Thromboembolism
Ortel, T. L. (2013) · Springer eBooks · doi:10.1007/978-3-319-01812-6_21 · Cited by 1
Diagnosis and Treatment of Deep Vein Thrombosis and Pulmonary Embolism After Major Joint Surgery
Monréal, M., & Arcelus, J. I. (2012) · Springer eBooks · doi:10.1007/978-1-4471-4336-9_4 · Cited by 1
Seguimiento de la tromboembolia pulmonar
Uresandi, F., Iruín, G., Gómez, B., & Uresandi, A. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)76450-9 · Cited by 2
Jiménez, D., Kopecna, D., de Miguel‐Díez, J., & Sueiro, A. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70882-0 · Cited by 2
Zatorowość płucna o wysokim ryzyku u 47-letniej pacjentki
Rozumko, A., Sominka, D., Gruchała, M., Gałąska, R., Rogowski, J. A., & Rynkiewicz, A. (2009) · Via Medica Journals · Cited by 1
Acute Phase Management of Venous Thromboembolism
Yamamoto, N., Unno, N., Suzuki, M., Mano, Y., Sano, M., Saito, T., & Sugisawa, R. (2013) · The Japanese Journal of Phlebology · doi:10.7134/phlebol.392 · Cited by 1
NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS
Laguta, P. S. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-1-5-15 · Cited by 1
Extended anticoagulation in venous thromboembolism disease. In favor
Fernández, M. C. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.04.003 · Cited by 1
Quel traitement anticoagulant au décours d’une embolie pulmonaire
Mao, R. L., Tromeur, C., & Couturaud, F. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2017.06.015 · Cited by 1
Anticoagulation for Proximal Deep Vein Thrombosis
Lee, A. I., & Lee, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_23 · Cited by 1
The Management of Venous Thromboembolic Disease
Obi, A. T., & Wakefield, T. W. (2018) · Advances in Surgery · doi:10.1016/j.yasu.2018.03.005 · Cited by 1
Task Force Report on the Management of Thrombosis in Antiphospholipid Syndrome
Ruiz‐Irastorza, G., Pengo, V., Tektonidou, M. G., Ruiz‐Arruza, I., Cuadrado, M. J., & Khamashta, M. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_11 · Cited by 1
Self-citationLong term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
“D-dimer levels assessed at time of discontinuation of anticoagulants, either during anticoagulant treatment or after discontinuation are associated with the risk for recurrent VTE [57,58].”
BackgroundPredicting risk indices of recurrence in the unprovoked venous thromboembolic disease
López-Núñez, J. J., & Sigüenza, P. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.05.029 · Cited by 1
Ateş, Y., Bingöl, Z., Okumuş, G., & Arseven, O. (2021) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2021.20679 · Cited by 1
Color Venous Duplex Ultrasound of the Lower Extremity in the Diagnosis of Deep Venous Thrombosis
Mansour, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-60626-8_40 · Cited by 1
Recent Insights into the Molecular and Cellular Contributions to Venous Thrombosis
Henke, P. K., Diaz, J. A., Myers, D. D., & Wakefield, T. W. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-906-8_3 · Cited by 1
Venous thromboembolism in women : risk factors and long term follow-up
Sonnevi, K. (2013) · Figshare · Cited by 1
Extension of anticoagulation after venous thromboembolism: Risk factors influencing the decision
Schulman, S. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617168 · Cited by 1
Utilidad de las pruebas básicas en el paciente con embolia pulmonar
Nauffal, D., Chacón, L. D., & Doménech-Clar, R. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)76449-2 · Cited by 1
ANALYSIS OF BROWNIAN DYNAMICS AND UNSTEADY PARTICLE-MOTION IN VISCOELASTIC FLUIDS
Azese, M. N. (2012) · ThinkTech (Texas Tech University) · doi:10.13140/rg.2.2.16607.82088 · Cited by 1
Metadata
- Authors
- Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., Lensing, A. W. A., & Tripodi, A.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Ospedale San Bortolo (IT)
- University of Perugia (IT)
- Azienda Ospedale - Università Padova (IT)
- Santa Maria Nuova Hospital (IT)
- Istituti Ospitalieri di Cremona (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-26
- Volume
- 355
- Issue
- 17
- Pages
- 1780-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2047986798
- Cited by
- 622
- References
- 25
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 16 · 2020: 34 · 2019: 22 · 2018: 20 · 2017: 19 · 2016: 40 · 2015: 41 · 2014: 40 · 2013: 38 · 2012: 53
- FWCI
- 35.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- D-dimer, anticoagulation duration, venous thromboembolism, deep vein thrombosis, pulmonary embolism, vitamin K antagonists, recurrence, major bleeding, unprovoked thrombosis, anticoagulation resumption
- MeSH terms
- Acenocoumarol, Adult, Aged, Aged, 80 and over, Anticoagulants, Antithrombins, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Follow-Up Studies, Hemorrhage, Humans, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Ultrasonography, Vitamin K, Warfarin, Proportional Hazards Models, Survival Analysis, Antiphospholipid Syndrome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.